share_log

通化东宝:痛风双靶点抑制剂Ⅱa期临床试验完成首例患者给药

JRJ Finance ·  May 6 06:20

通化东宝公告,痛风双靶点抑制剂(THDBH151片)Ⅱa期临床试验完成首例患者给药。截至本公告日,公司在该项目中研发投入约6662.90万元。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment